Immune escape by Epstein-Barr virus associated malignancies.
- Münz C Viral Immunobiology, Institute of Experimental Immunology, University Hospital of Zurich, Zurich, Switzerland. christian.muenz@usz.ch
- Moormann A
- 2008-11-11
Published in:
- Seminars in cancer biology. - 2008
Antigens, Viral
CD4-Positive T-Lymphocytes
CD8-Positive T-Lymphocytes
Cancer Vaccines
Epstein-Barr Virus Infections
HIV Infections
Herpesvirus 4, Human
Humans
Malaria, Falciparum
Neoplasms
Tumor Escape
Virus Activation
Virus Latency
English
Persistent Epstein-Barr virus (EBV) infection remains asymptomatic in the majority of virus carriers, despite the potent growth transforming potential of this virus. The increased frequency of EBV associated B cell lymphomas in immune compromised individuals suggests that tumor-free chronic infection with this virus is in part due to immune control. Here we discuss the evidence that loss of selective components of EBV specific immunity might contribute to EBV associated malignancies, like nasopharyngeal carcinoma, Burkitt's and Hodgkin's lymphoma, in otherwise immune competent patients. Furthermore, we discuss how current vaccine approaches against EBV might be able to target these selective deficiencies.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1016/j.semcancer.2008.10.002
- PMID 18996483
- Persistent URL
- https://sonar.ch/global/documents/280528
Statistics
Document views: 4
File downloads:
- fulltext.pdf: 0